Related Experiment Video
Updated: Jan 14, 2026

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
Role of cDC2 in priming CD8+ T cells in cancer
Ahmed E I Hamouda1,2, Damya Laoui3,2
1Lab of Dendritic Cell Biology and Cancer Immunotherapy, VIB Center for Inflammation Research, Brussels, Belgium.
Abstract:
Type 2 conventional dendritic cell (cDC2) gene signature was shown to be associated with better overall survival in patients with lung cancer and a fraction of patients with breast carcinoma, indicating that they may possess antitumoral function. Nevertheless, unraveling the antitumoral role of cDC2s proved to be challenging due to their complex development and heterogeneity. Here, we discuss findings showcasing the ability of cDC2s to prime cytotoxic CD8+ T cells upon acquiring a distinct activation state, leading to effective immune responses against viral infections and cancer. This cDC2 activation state is induced by type I interferon (IFN) and consequently shows enrichment in IFN-stimulated genes.
Related Concept Videos
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Inhibition of Cdk Activity
Anaphase Promoting Complex
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Tumor Immunotherapy

